What is the appropriate dosage of Synjardy (empagliflozin + metformin) for an adult with type 2 diabetes and normal renal function?

Synjardy Dosage

For adults with type 2 diabetes and normal renal function (eGFR ≥60 mL/min/1.73 m²), start Synjardy at empagliflozin 10 mg/metformin 500-1000 mg twice daily with meals, titrating metformin gradually to reduce GI side effects, with a maximum dose of empagliflozin 25 mg/metformin 2000 mg total daily. 1

Initial Dosing Strategy

When initiating Synjardy, your starting dose depends on the patient's current regimen:

• Metformin-naïve patients: Start with empagliflozin 10 mg/metformin 500 mg twice daily, increasing metformin by 500 mg weekly as tolerated to minimize gastrointestinal adverse effects 1

• Already on metformin: Switch to Synjardy maintaining the same total daily metformin dose (up to 2000 mg/day) plus empagliflozin 10 mg daily 1

• Already on empagliflozin: Add metformin starting at 1000 mg total daily, maintaining the same empagliflozin dose 1

The empagliflozin component provides cardiovascular and renal benefits at 10 mg daily—the dose tested in major outcomes trials 2. You do not need to titrate empagliflozin for CV/renal protection, though you may increase to 25 mg daily if additional glucose lowering is needed 1.

Dosing by Renal Function

Renal function critically determines Synjardy eligibility and dosing:

• eGFR ≥60: No dose adjustment needed; use full doses 1

• eGFR 45-59: Do not initiate Synjardy due to metformin component; if already established on therapy, continue with caution and consider reducing metformin to 1000 mg daily 3, 1

• eGFR 30-44: Reduce metformin to half the maximum dose (1000 mg daily maximum); empagliflozin provides minimal glucose-lowering but continue for cardiovascular/renal benefits 3, 1

• eGFR <30: Synjardy is contraindicated due to metformin's lactic acidosis risk 1

Monitor eGFR at least annually when ≥60, and every 3-6 months when <60 3, 4. The KDIGO 2022 guidelines emphasize that once SGLT2 inhibitors are started, they can be continued even as eGFR declines below the initiation threshold, as cardiovascular and renal benefits persist 3.

Administration Details

• Synjardy (immediate-release): Take twice daily with meals 1
• Synjardy XR (extended-release): Take once daily with morning meal 1
• Swallow tablets whole—do not split, crush, dissolve, or chew 1

Taking with food reduces metformin GI side effects and optimizes absorption 1.

Pediatric Dosing (Ages 10+)

For pediatric patients aged 10 years and older with type 2 diabetes:

• Individualize based on current regimen
• Maximum: empagliflozin 25 mg/metformin 2000 mg total daily
• Administer twice daily with meals, using gradual metformin titration 1

Pharmacokinetic studies confirm empagliflozin 10-25 mg produces similar exposure in adolescents (10-17 years) as in adults 1.

Critical Dosing Modifications

Discontinue Synjardy temporarily in these situations:

1. Before iodinated contrast procedures if eGFR <60, history of liver disease, alcoholism, heart failure, or intra-arterial contrast use. Restart only after confirming stable renal function 48 hours post-procedure 1

2. At least 3 days before surgery or procedures with prolonged fasting to prevent ketoacidosis risk. Resume when clinically stable and eating 1

3. During critical illness or prolonged fasting when ketosis risk increases 4

Dose Adjustments with Concomitant Medications

When adding Synjardy to patients on:

• Insulin or sulfonylureas: Reduce insulin by ~20% or discontinue/reduce sulfonylurea dose to prevent hypoglycemia 2
• Diuretics: Consider reducing diuretic dose before starting to mitigate volume depletion risk 2

Common Pitfalls to Avoid

• Don't initiate in volume-depleted patients—correct volume status first 1
• Don't use for type 1 diabetes—increases diabetic ketoacidosis risk 1
• Don't forget vitamin B12 monitoring—metformin causes deficiency after 4+ years of use 3
• Don't overlook genital hygiene counseling—empagliflozin increases genital mycotic infection risk (3.7-4.7%) 2, 5

Evidence Base

The combination of empagliflozin 10-25 mg with metformin reduces HbA1c by 0.7-0.8% more than placebo when added to metformin 5, with additional benefits of 2-2.5 kg weight loss 5 and systolic BP reduction of 3-4 mmHg 5. Initial combination therapy produces HbA1c reductions of 1.9-2.1% in treatment-naïve patients 6. The EMPA-REG OUTCOME trial established empagliflozin's cardiovascular mortality benefit (38% reduction) at the 10 mg dose 2, supporting the recommendation to start at 10 mg for organ protection regardless of glucose-lowering needs.